Mediators of neutrophil function in children with protracted bacterial bronchitis

Chest

Volumn 146, Issue 4, 2014, Pages 1013-1020

  Baines, Katherine J ^a,b   Upham, John W ^c   Yerkovich, Stephanie T ^c,d   Chang, Anne B ^e,f   Marchant, Julie M ^c,e   Carroll, Melanie ^c   Simpson, Jodie L ^a,b   Gibson, Peter G ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 2; ALPHA DEFENSIN 3; CHEMOKINE RECEPTOR CXCR2; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; PELLINO 1; UNCLASSIFIED DRUG;

ARTICLE; BRONCHITIS; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INFANT; LEUKOCYTE FUNCTION; LUNG LAVAGE; MALE; MEDIATOR RELEASE; NEUTROPHIL; NEUTROPHILIA; PATHOGENESIS; PROTEIN EXPRESSION; PROTRACTED BACTERIAL BRONCHITIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING; BACTERIAL INFECTION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PRESCHOOL CHILD;

ALPHA-DEFENSINS; BACTERIAL INFECTIONS; BLOTTING, WESTERN; BRONCHITIS; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1BETA; MALE; NEUTROPHILS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84907921105     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0131     Document Type: Article

References (28)

1. Chang AB, Landau LI, Van Asperen PP, et al; Thoracic Society of Australia and New Zealand. Cough in children: definitions and clinical evaluation. Med J Aust. 2006; 184 (8): 398 - 403.
2. Marchant J, Masters IB, Champion A, Petsky H, Chang AB. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax. 2012; 67 (8): 689 - 693.
3. Donnelly D, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. Thorax. 2007; 62 (1): 80 - 84.
4. Gibson PG, Chang AB, Glasgow NJ, et al; CICADA. CICADA: Cough in children and adults: diagnosis and assessment. Australian cough guidelines summary statement. Med J Aust. 2010; 192 (5): 265 - 271.
5. Shields MD, Bush A, Everard ML, McKenzie S, Primhak R; British Thoracic Society Cough Guideline Group. BTS guidelines: recommendations for the assessment and management of cough in children. Thorax. 2008; 63 (suppl 3): Iii1 - iii15.
6. Marchant JM, Gibson PG, Grissell TV, Timmins NL, Masters IB, Chang AB. Prospective assessment of protracted bacterial bronchitis: Airway inflammation and innate immune activation. Pediatr Pulmonol. 2008; 43 (11): 1092 - 1099.
7. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol. 2011; 127 (1): 153 - 160.
8. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Systemic upregulation of neutrophil a -defensins and serine proteases in neutrophilic asthma. Thorax. 2011; 66 (11): 942 - 947.
9. Chang AB, Cox NC, Faoagali J, et al. Cough and refl ux esophagitis in children: Their co-existence and airway cellularity. BMC Pediatrics. 2006; 6 : 4.
10. Chang AB, Newman RG, Carlin JB, Phelan PD, Robertson CF. Subjective scoring of cough in children: Parentcompleted vs child-completed diary cards vs an objective method. Eur Respir J. 1998; 11 (2): 462 - 466.
11. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012; 11 (8): 633 - 652.
12. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. A nnu Rev Immunol. 2009; 27 : 229 - 265.
13. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1- independent activation of interleukin-1 b in neutrophil-predominant inflammation. Arthritis Rheum. 2009; 60 (12): 3642 - 3650.
14. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010; 3 (105): cm1.
15. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1 a and the Nlrp3/caspase-1/IL-1 b axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J. 2011; 38 (5): 1019 - 1028.
16. Eickmeier O, Huebner M, Herrmann E, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine. 2010; 50 (2): 152 - 157.
17. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2013; 55 (1): 27 - 34.
18. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011; 184 (6): 662 - 671.
19. Cai S, Batra S, Wakamatsu N, Pacher P, Jeyaseelan S. NLRC4 inflammasomemediated production of IL-1 b modulates mucosal immunity in the lung against gram-negative bacterial infection. J Immunol. 2012; 188 (11): 5623 - 5635.
20. Marriott HM, Gascoyne KA, Gowda R, et al. Interleukin-1 b regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages. Infect Immun. 2012; 80 (3): 1140 - 1149.
21. Griffiths MJ, Ooi MH, Wong SC, et al. In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1 b, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. J Infect Dis. 2012; 206 (6): 881 - 892.
22. Bennett JA, Prince LR, Parker LC, et al. Pellino-1 selectively regulates epithelial cell responses to rhinovirus. J Virol. 2012; 86 (12): 6595 - 6604.
23. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptordependent responses by IRAK1 and IRAK2. Nat Immunol. 2008; 9 (6): 684 - 691.
24. Baines KJ, Hsu AC, Tooze M, Gunawardhana LP, Gibson PG, Wark PA. Novel immune genes associated with excessive infl ammatory and antiviral responses to rhinovirus in COPD. Respir Res. 2013; 14 : 15.
25. Konrad FM, Reutershan J. CXCR2 in acute lung injury. Mediators Inflamm. 2012; 2012 : 740987.
26. Chen Q, Jin Y, Zhang K, et al. Alarmin HNP-1 promotes pyroptosis and IL-1 b release through different roles of NLRP3 inflammasome via P2X7 in LPSprimed macrophages. Innate Immun. 2014; 20 (3): 290 - 300.
27. Zhang H, Porro G, Orzech N, Mullen B, Liu M, Slutsky AS. Neutrophil defensins mediate acute infl ammatory response and lung dysfunction in dose-related fashion. Am J Physiol Lung Cell Mol Physiol. 2001; 280 (5): L947 - L954.
28. Sakamoto N, Mukae H, Fujii T, et al. Differential effects of alpha- and betadefensin on cytokine production by cultured human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005; 288 (3): L508 - L513.